Harriman

Researchers are studying whether using the Quest AD-Detect blood test during hospitalization for cognitive issues like delirium or encephalopathy can help identify underlying Alzheimer's disease earlier. The trial focuses on patients aged 60 to 90 years who have no prior diagnosis of dementia but are currently hospitalized with cognitive problems that may be caused by toxic or metabolic conditions. The study aims to see if this blood test can distinguish Alzheimer's disease from other causes of cognitive impairment in the hospital setting. Participants will have blood collected while they are hospitalized, and this blood will be tested using the Quest AD-Detect blood test. After discharge, patients will have a follow-up visit with the Neurology Clinic six months later to review their risk assessment and diagnosis based on the blood test results. This approach helps researchers evaluate the test's ability to detect Alzheimer's disease early in hospitalized patients with cognitive symptoms. During the study, researchers will monitor the percentage of patients who received a cognitive diagnosis and test positive for Alzheimer's biomarkers from enrollment through the six-month follow-up. The study includes clinical evaluations and testing during hospitalization and a follow-up appointment to assess outcomes. This process helps determine the effectiveness of the blood test in identifying Alzheimer's disease in this patient group over time.